Navigation Links
Survival Rate of Cancer Patients in Korea Ranked in the Top in the World
Date:2/6/2012

SEOUL, South Korea, Feb. 6, 2012 /PRNewswire-Asia/ -- As the whole world battles against cancer, the survival rate of cancer patients in Korea has shown a great improvement. Cancer is still the number one cause of death in Korea, but about half of Korean cancer patients have, in recent times, managed to survive for more than ten years, which illustrates that world class cancer treatments are available in Korea.

The Korean government recently announced that the survival rate of Korean cancer patients had improved from 59.5% in 2008 to 62.0% in 2009, while the cancer mortality rate showed a 19% decrease in 2006 and a 21% decrease in 2008. In addition, the 2011 Health Care Quality Indicators released by OECD member countries indicated that Korea excelled in the treatment of uterine cancer and that its survival rate for stomach cancer, 65.3%, well surpassed those of the USA (26%), Europe (24.9%), Japan (62.1%) and Canada (22%). In addition, the survival rate from thyroid cancer in Korea is 99.7% while that of breast cancer is 90.6%.

Similarly, Korean Ministry of Health & Welfare carried out an interim assessment of the '10-Year Plan to Conquer Cancer' and found out that the plan had exceeded its initial objective in 2011. Thus, the Ministry upgraded the survival rate target by 2015 from 54% to 67% following the deliberation by the National Cancer Management Committee. Cancer survival rate refers to the percentage of people able to survive five years after being diagnosed with and treated for cancer. It actually means the complete recovery rate.

Such excellent survival rates for Korean cancer patients have been due to the continuous efforts of the government to manage cancer and advance the medical technology. Korea has been building its reputation in robot-assisted surgery, a cutting edge cancer treatment technology, which has every year attracted many medical experts from Japan, Taiwan and many other countries to the National Cancer Center
'/>"/>

SOURCE Korea Health Development Institute
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Study Published in Neuro-Oncology Journal Shows Brain Tumor Eradication and Prolonged Survival in Mice Treated With Toca 511 and 5-FC
2. Phase III Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
3. Phase 3 Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
4. Clinical Trials Are Key to Doubling the Survival Rate for Pancreatic Cancer
5. Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
6. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
7. Updated Survival Data from Study Comparing TTF™ (Tumor Treating Fields) Therapy to Best Standard Chemotherapy for Recurrent Glioblastoma Reported at the 16th Annual Scientific Meeting of the Society for NeuroOncology
8. The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer
9. Health of Recipients and Quality of Donor are Greater Factors in Survival than Metabolic Factors
10. bioTheranostics CancerTYPE ID® Linked With Improved Clinical Outcome and Longer Survival
11. Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a ... of innovative therapies for the treatment of acute pain, ... for the three and six months ended June 30, ... July 23, 2015, the Committee for Medicinal Products for ... for the management of acute moderate-to-severe post-operative pain in ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... 2010 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... quarter ended September 30, 2010, on Tuesday, November 9, 2010 ... Company recently held an investor conference call on October 11th, ... with the release of the Company,s third quarter results.  The ...
... The Phase 3 results from the ADVANCE study ... The study reports an improvement in treatment discontinuation rates ... and demonstrates an increase in sustained viral response (SVR) ... endpoint for this study was SVR 24 weeks after ...
Cached Medicine Technology:Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 3
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is ... health conditions, pictures and medical art can be essential. StayWell, a health solutions company, ... Krames Patient Education solutions have been used by physicians and other health care providers ...
(Date:8/4/2015)... Farmingdale, New York (PRWEB) , ... August 04, ... ... for exceptional dietary supplement manufacturing, label design, product packaging, and fulfillment services, joined ... Workplace Challenge. The event was held on Tuesday, July 28th at Jones ...
(Date:8/4/2015)... Morristown & Montclair, NJ (PRWEB) , ... August 04, 2015 , ... ... certificate program in Arts and Health, the first of its kind in New Jersey, ... The University’s College of the Arts and Graduate School partnered with Atlantic Health System, ...
(Date:8/4/2015)... Las Vegas, Nevada (PRWEB) , ... August 04, ... ... INTIMATELY FEMALE, a striking contemporary look at unique artistic expressions from a diverse ... Motel inside the Life Is Beautiful Music & Art Festival on September 25-27, ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... brings an automatic end to driving, says the August 2015 Harvard Health Letter. ... okay to drive. It requires an individual assessment of skills," says Lissa Kapust, ...
Breaking Medicine News(10 mins):Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2
... artificial heart could prevent death in critically ill patients ... . The artificial heart implant improved survival rates before ... ,The artificial heart was found to be a ... did not improve with standard therapy and who were ...
... drug combined with sunlight helps the body tan quicker without ... that is similar to the body’s hormone that regulates skin ... can induce tanning in human volunteers who are known to ... Researchers conducted three different clinical trials to see if MT-1 ...
... research shows a significant improvement in treatment for a specific ... seminoma is typically treated by // removal of the testicle ... a second cancer in another organ up to 20 years ... a single course of the drug carboplatin and more than ...
... risk of developing a variety of skin conditions such ... many of these problems can be averted by correcting ... instrument. ,Researchers found the most common skin disorders ... of an instrument and irritations caused by prolonged, intense ...
... drug that helps reduce the risk of reactivating the ... with chemotherapy for breast cancer.An estimated 12 percent // ... and these patients are at risk of developing HBV ... in varying degrees of liver damage that may lead ...
... has shed light on how brain controls movement say researchers. ... make its whiskers twitch, a discovery researchers say //could help ... scientists develop devices paralyzed people could control, such as robotic ... the part of the brain that controls movement contains so ...
Cached Medicine News:
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
... Specifically designed for patients who experience severe ... Day prevents tears in fibrous tissue that ... during those first steps in the morning. ... the pain associated with plantar fasciitis and ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Resilient insole has a series of removable hexagons for tailored pressure relief....
Medicine Products: